Insights for AI Startups' Global Leap(venturesquare.net)
Writing language: KoreanRead in the original language
Plain summary
- Sixsense and J&P Medi are accelerating their overseas expansion by being selected for Y Combinator's Summer 2026 batch and the Unicorn Bridge program.
- While the schedules for batches and support programs move quickly, the pace at which manufacturing sites and clinical trials are adopted do not move at the same rhythm.
- The variable that can advance the timetable is the speed of collecting data and proving efficiency on site rather than just prior information.
- Participating in the programs should be viewed not as the completion of overseas expansion but as the start of validation.
Have you run into something like this? Tell us in a line or two what you did. You do not need to know the product.